Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA447

Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults, only if:

• their tumours express PD-L1 with at least a 50% tumour proportion score and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations

• pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression

• the conditions in the managed access agreement for pembrolizumab are followed.

1.2This recommendation is not intended to affect treatment with pembrolizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta447